Skip to main content

Interventional Oncology Devices Market Future Outlook 2021 to 2030

 Interventional oncology procedures are suitable for those cancer patients who do not respond to chemotherapy and are not fit for surgery. Interventional oncology procedures require devices such as embolization and ablation devices, as well as an array of support devices such as catheters.

The global interventional oncology devices market is an emerging market in the medical device ecosystem. The market comprises various key medical device companies and several start-ups developing advanced solutions for cancer treatment. Furthermore, the market also has unique products in the pipeline that would further improve the technology integration in cancer treatment. 

The global interventional oncology devices market report highlights that the market was valued at $2,429.2 million in 2020 and is expected to reach $7,861.1 million by the end of 2030. The market is expected to grow at a CAGR of 12.35% during the forecast period from 2021 to 2030.



Global Interventional Oncology Devices Market (by Cancer Type)

The global interventional oncology devices market, on the basis of cancer type, has been segmented into liver cancer, lung cancer, kidney cancer, prostate cancer, and other cancer.

The liver cancer segment accounted for the highest share of the market, which can be attributed to high consumption of alcohol, chronic viral hepatitis, liver cirrhosis, and rise in the obesity index globally. Moreover, liver cancer is less common in the U.S. than in sub-Saharan Africa and South Asian countries. Liver cancer accounts for more than 70,000 deaths each year.

Global Interventional Oncology Devices Market (by Product Type)

The global interventional oncology devices market, on the basis of product type, has been segmented into ablation devices, embolization devices, supporting devices, and next-generation devices.

Ablation is used as the first line of treatment in a few cases of hepatocellular carcinoma, and it is also considered an important option for patients who are either not eligible for surgery or have failed chemotherapy.  Furthermore, advancements in interventional oncology would propel the growth of next-generation devices in the forecast period 2021-2030.

Global Interventional Oncology Devices Market (by End User)

The global interventional oncology devices market, on the basis of end users, has been segmented into three categories, namely, hospitals, ambulatory surgical centers (ASCs), and others.

Hospitals are at the forefront in terms of interventional oncology devices adoption. The increasing focus on evidence-based care has been one of the strongest drivers for the adoption of interventional oncology.

The growing prominence for outpatient surgeries and rising establishments of ASCs are the leading factors promoting the market's growth for the global interventional oncology devices. The adoption of interventional oncology devices in ambulatory surgical centers can be boosted by prioritizing the increasing demand for minimally invasive surgeries. 

Global Interventional Oncology Devices Market (by Region)

The different regions covered under the global interventional oncology devices market include North America, Europe, Asia-Pacific, and Rest-of-the-World.

North America dominates the global interventional oncology devices market due to high prevalence of cancer, growing geriatric population, and high reimbursement rates. The Asia-Pacific interventional oncology devices market is one of the lucrative markets with immense potential for expansion by key players of the global interventional oncology market. The Asia-Pacific interventional oncology devices market is expected to grow at the fastest rate in the forecast period, and this can be attributed to the massive geriatric population base, driving the demand for minimally invasive and non-invasive surgical procedures

The potential opportunities that are likely to boost the growth of the global interventional oncology devices market are high growth opportunity in the emerging economies, and emergence of local companies in Asia-Pacific and the Middle East and Africa.

Request a Sample - https://bisresearch.com/requestsample?id=1215&type=download

Comments

Popular posts from this blog

Microbiome Therapeutics Market Growth, Segmentation, Opportunity and Forecast to 2032

  Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders, cancer indications among others. The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032. The existing   microbiome therapeutics market    is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market. Impact of COVID-19 There were numerous consequences due to the COVID-19 pandemic, especially...

Ligase Market Opportunities, Strategies, Share, Segmentation, In-depth Analysis 2032

  The global ligase market is progressing rapidly with a significant increase in the research and development activities pertaining to a wide range of ligase product for disease detection, accentuating their criticality in healthcare. Ligase enzyme has a critical role in the molecular diagnostics approach, as it ensures the safe and effective application of targeted therapeutics. Most of the players in the global ligase market offer products encompassing the ligation kits and enzymes. The global  ligase market  is projected to reach $651.4 million by 2032 from $371.2 million in 2021, at a CAGR of 5.29% during the forecast period 2022-2032. The growth in the global ligase market is expected to be driven by factors such as the increasing prevalence of infectious and genetic diseases on a global level, rising awareness of enzyme based diagnostic testing and significant number of funding for executing research and development.   Impact Several techniques are employed in ...

PD-1/PDL-1 Inhibitor Market Growth Prospects, Emerging Trends and Forecast to 2032

  PD-1/PDL-1 inhibitors are immune-therapeutic agents used in the treatment of various cancer indications, mostly in the advanced stages. PD-1/PDL-1 inhibitors are monoclonal antibodies majorly of IgG1 and IgG4 types to be administered to patients via injection The current market already has seven approved products in the U.S. and a large number of research activities are currently undergoing in this segment generating interest of commercial as well as academic research institutions. In the current period of precision medicine and providing targeted treatment, identification of target patient has become very important as well as complicated. With the emergence of diagnostic test identifying predictive biomarkers, the selection and administration of targeted treatment has become comparativlely conveninent and efficient. PD-1/PDL-1 inhibitors market   are majorly indicated for the treatment of advanced cases of different cancer indications. The PD-1/PDL-1 inibitor treatment has ...